All the Active Ingredient Drugs
Yellow Fever Vaccine (Live) (strain 17 D-204) ≥1000 WHO standard units. VIAL/PREFILLED SYRINGE (pwdr.) +
diluent: 1 + 1 x 0.5 ml. Primary vaccin.: The vaccin. should be given at least 10 d. before entering an endemic area since protective immun. may not be achieved until at least this time has elapsed.
Adult.: a single dose of 0.5 ml of the reconstit. vaccine.
Paed. pts.: Child.≥9 mnths.: a single dose of 0.5 ml of the reconst. vaccine.
Child. from 6- 9 mnths. of age: Vaccin. against yellow fever is not recomm. in child. aged from 6 mnths. up to 9 mnths. except in specific circumstances. See lit.
Active immuniz. against yellow fever in persons: Travell. to, passing through or living in an endemic area.
Travell. to any country that requires an internat. certificate of vaccinat. for entry (which may or may not Depend on the previous itinerary).
Handl. potentially infect. materials (e.g. lab. personnel).
C/I: Hypersens. to the active substan. to eggs or chicken proteins.
Sev. hypers. reactions (e.g., anaphylaxis) after a previous dose of any yellow fever vaccine.
Child. less than 6 mnths.
Immunosuppres., whether congen., idiopath. or as a result of tmt. with system. steroids (greater than the standard dose of topical or inhaled steroids), radiother. or cytotoxic drugs.
Hist. of thymus dysfunction (includ. myasthenia g., thymoma, thymectomy).
Symptom. HIV infec.
Asymptom. HIV infect. when accompany. by evidence of impair. immun. funct.
Moder./sev. febrile illness or acute illness.
History of thymus dysfunct. (includ. myasthenia g., thymoma, thymectomy).
